AC Immune SA announced the termination of the Research Collaboration and License Agreement dated November 6, 2006, by and between the Company and Genentech Inc., and the Research Collaboration and License Agreement dated June 15, 2012, by and among the Company, Genentech Inc. and F-Hoffman La-Roche Ltd. Following the termination of these two agreements, the Company will regain all global rights to crenezumab and semorinemab. AC Immune SA announced that the Company will regain all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab following termination of the collaboration agreements with Genentech and Roche. Both antibodies have been evaluated in clinical studies for Alzheimer?s disease (AD).

AC Immune will also regain rights to existing GMP drug-product for clinical testing as well as associated data generated under each of the agreements. AC Immune will carefully review and evaluate available data sets, including the final open label extension results from the Lauriet trial when they become available and are received in full by AC Immune, before decisions are made on potential further development and other opportunities.